Barinka Cyril, Parry Graham, Callahan Jennifer, Shaw David E, Kuo Alice, Bdeir Khalil, Cines Douglas B, Mazar Andrew, Lubkowski Jacek
Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA.
J Mol Biol. 2006 Oct 20;363(2):482-95. doi: 10.1016/j.jmb.2006.08.063. Epub 2006 Aug 26.
Recent studies indicate that binding of the urokinase-type plasminogen activator (uPA) to its high-affinity receptor (uPAR) orchestrates uPAR interactions with other cellular components that play a pivotal role in diverse (patho-)physiological processes, including wound healing, angiogenesis, inflammation, and cancer metastasis. However, notwithstanding the wealth of biochemical data available describing the activities of uPAR, little is known about the exact mode of uPAR/uPA interactions or the presumed conformational changes that accompany uPA/uPAR engagement. Here, we report the crystal structure of soluble urokinase plasminogen activator receptor (suPAR), which contains the three domains of the wild-type receptor but lacks the cell-surface anchoring sequence, in complex with the amino-terminal fragment of urokinase-type plasminogen activator (ATF), at the resolution of 2.8 A. We report the 1.9 A crystal structure of free ATF. Our results provide a structural basis, represented by conformational changes induced in uPAR, for several published biochemical observations describing the nature of uPAR/uPA interactions and provide insight into mechanisms that may be responsible for the cellular responses induced by uPA binding.
最近的研究表明,尿激酶型纤溶酶原激活剂(uPA)与其高亲和力受体(uPAR)的结合,协调了uPAR与其他细胞成分的相互作用,这些细胞成分在多种(病理)生理过程中发挥关键作用,包括伤口愈合、血管生成、炎症和癌症转移。然而,尽管有大量关于uPAR活性的生化数据,但对于uPAR/uPA相互作用的确切模式或uPA/uPAR结合时假定的构象变化知之甚少。在此,我们报告了可溶性尿激酶纤溶酶原激活剂受体(suPAR)的晶体结构,其包含野生型受体的三个结构域,但缺少细胞表面锚定序列,与尿激酶型纤溶酶原激活剂(ATF)的氨基末端片段形成复合物,分辨率为2.8埃。我们还报告了游离ATF的1.9埃晶体结构。我们的结果为一些已发表的描述uPAR/uPA相互作用性质的生化观察提供了一个以uPAR中诱导的构象变化为代表的结构基础,并深入了解了可能导致uPA结合诱导的细胞反应的机制。